After finishing at $8.25 in the prior trading day, Accolade Inc (NASDAQ: ACCD) closed at $8.58, up 4.00%. On the day, 813862 shares were traded.
Ratios:
Our goal is to gain a better understanding of ACCD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.31 and its Current Ratio is at 2.31. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $16.
On January 03, 2024, Barclays started tracking the stock assigning a Equal Weight rating and target price of $13.Barclays initiated its Equal Weight rating on January 03, 2024, with a $13 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 11 ’24 when SINGH RAJEEV sold 667 shares for $8.85 per share. The transaction valued at 5,902 led to the insider holds 746,731 shares of the business.
Barnes Stephen H. sold 265 shares of ACCD for $2,345 on Apr 11 ’24. The Chief Financial Officer now owns 178,211 shares after completing the transaction at $8.85 per share. On Apr 11 ’24, another insider, Cavanaugh Robert N, who serves as the President of the company, sold 253 shares for $8.85 each. As a result, the insider received 2,239 and left with 172,098 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.71 while its Price-to-Book (P/B) ratio in mrq is 1.52.
Stock Price History:
Over the past 52 weeks, ACCD has reached a high of $17.00, while it has fallen to a 52-week low of $6.33.
Shares Statistics:
A total of 73.09M shares are outstanding, with a floating share count of 69.68M. Insiders hold about 9.98% of the company’s shares, while institutions hold 78.72% stake in the company.
Earnings Estimates
Its stock is currently analyzed by ACADIA Pharmaceuticals Inc. different market analysts. The consensus estimate for the next quarter is $8.49, with high estimates of $5.02 and low estimates of $8.58.
Analysts are recommending an EPS of between $Industrials and $Healthcare for the fiscal current year, implying an average EPS of $Energy.
